Royalty Pharma plc (RPRX)
Royalty Pharma plc Net Income
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | $581.4M | $565.9M | $1,210.0M | $1,377.7M | $2,348.5M | $495.2M | $478.8M | $42.8M | $1,134.8M |
Royalty Pharma plc (RPRX) Net Income comparison analysis
RPRX key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
investors
worldwide
FAQ
1) What is Royalty Pharma plc's Net Income?
As of today, Royalty Pharma plc's last 12-month Net Income is $1,145.1M, based on the financial report for Sep 30, 2024 (Q3 2024).
2) What is Royalty Pharma plc's Net Income growth rate?
Over the last year, Royalty Pharma plc's Net Income growth was 3,676.1%. The average annual Net Income growth rates for Royalty Pharma plc have been 5.6% over the past three years, 4.3% over the past five years.
3) Is Royalty Pharma plc's Net Income growth rate Good?
Over the last year, Royalty Pharma plc's Net Income growth was 3,676.1%, which is higher than industry growth of (0.1%). It indicates that Royalty Pharma plc's Net Income growth is Good.